Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Protagonist Therapeutics Inc’s stock clocked out at $39.05, up 1.56% from its previous closing price of $38.45. In other words, the price has increased by $1.56 from its previous closing price. On the day, 1.03 million shares were traded.
Ratios:
To gain a deeper understanding of PTGX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.11. For the most recent quarter (mrq), Quick Ratio is recorded 12.48 and its Current Ratio is at 12.48. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 06, 2024, initiated with a Neutral rating and assigned the stock a target price of $47.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $62.
On November 05, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $58.Wedbush initiated its Outperform rating on November 05, 2024, with a $58 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 19 ’25 when PATEL DINESH V PH D sold 5,359 shares for $38.18 per share. The transaction valued at 204,607 led to the insider holds 540,260 shares of the business.
MOLINA ARTURO MD sold 26,000 shares of PTGX for $1,162,280 on Nov 27 ’24. The Chief Medical Officer now owns 46,444 shares after completing the transaction at $44.70 per share. On Nov 26 ’24, another insider, MOLINA ARTURO MD, who serves as the Chief Medical Officer of the company, sold 5,529 shares for $45.60 each. As a result, the insider received 252,122 and left with 46,444 shares of the company.
Valuation Measures:
As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 9.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.52 while its Price-to-Book (P/B) ratio in mrq is 3.53.
Stock Price History:
Over the past 52 weeks, PTGX has reached a high of $48.89, while it has fallen to a 52-week low of $24.22. The 50-Day Moving Average of the stock is 2.63%, while the 200-Day Moving Average is calculated to be -1.43%.
Shares Statistics:
A total of 61.04M shares are outstanding, with a floating share count of 57.79M. Insiders hold about 5.85% of the company’s shares, while institutions hold 100.48% stake in the company.
